ClinicalTrials.gg
WithdrawnNCT06341647Updated Jan 24, 2025

Phase 1 Clinical Trial to Evaluate the Safety and Anti-Tumor Activity of AB-201

A Phase 1 interventional study of AB-201 and Cyclophosphamide in Breast Cancer, Gastric Cancer and Gastroesophageal Junction Adenocarcinoma, sponsored by GC Cell Corporation. Withdrawn. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-01-24.

Sponsored by GC Cell Corporation · Phase 1, Interventional, and Treatment

How we know

Why this study was withdrawn
Determined that enrollment would be limited due to the change in care setting.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
0
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Study summary

This clinical trial will enroll subjects with HER2+ solid tumors and is conducted in two phases, which are phase 1a and phase 1b. The primary objective of phase 1 is to determine the safety and tolerability of AB-201 in subjects with advanced HER2+ solid tumors.

Read the detailed description

This is a Phase 1, multicenter study designed to evaluate the safety, tolerability, and efficacy of AB-201 in subjects with advanced HER2+ solid tumors (specifically, breast and gastric/GEJ cancers).

The Phase 1 will be conducted in two parts, an initial dose escalation stage followed by a dose expansion stage.

Study participation for each subject begins with up to 28 days (1 month) of screening following written informed consent, then lymphodepletion treatment, followed by AB-201. Up to 3 doses of AB-201 may be administered. All subjects will be monitored for a total duration of 18 months of follow up from the first dose administration of AB-201.

02

Conditions studied

  • Breast Cancer
  • Gastric Cancer
  • Gastroesophageal Junction Adenocarcinoma
03

In context

Breast Neoplasms

14,855 studies on the registry are indexed under Breast Neoplasms; 3,321 are open to participants now.

Browse Breast Neoplasms studies →

Lead sponsor

GC Cell Corporation is the lead sponsor of 15 studies on the registry; 2 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • performance status 0 to 1.
  • confirmed expressed breast or gastric/GEJ cancer IHC ≥ 2+ within 6 months prior to study entry.
  • Confirmed diagnosis of an advanced/unresectable or HER2+ breast or gastric/GEJ cancer that is to, or intolerable of standard treatment, or for which no standard treatment is available.
  • Must have received prior cancer therapy: Subjects with breast cancer must have received ≥ 3 prior systemic therapies; subjects with gastric/GEJ cancer must have received ≥ 2 prior systemic therapy(ies); subjects with IHC 3+ or IHC 2+/ISH+ cancers must have received previous treatment with a HER2-targeting therapy.

Exclusion criteria

Exclusion Criteria:

  • Known past or current other than inclusion diagnosis.
  • Known cardiac disease.
  • Active central nervous system (CNS) , or involvement of the CNS, unless there is a history of at least 3 months of sustained remission.
  • Unresolved toxicities from prior anticancer therapy.
  • Ongoing uncontrolled systemic infections requiring antibiotic, anti-fungal, or anti-viral therapy.
  • History of sensitivity or intolerance to cyclophosphamide or fludarabine.
  • Currently Pregnant or lactating
  • Severe disease progression or health deterioration within 2 weeks prior to lymphodepletion regimen.
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

HER2

HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.

In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
0 participants (actual)

Study arms

  • Experimental
    Phase 1a Dose Escalation

    * Dose Escalation of AB-201 in advanced metastatic breast cancer, gastric or gastroesophageal junction adenocarcinoma with HER2 overexpression * Interventions: * Drug: AB-201 * Drug: Cyclophosphamide * Drug: Fludarabine

    Drug: AB-201 · Drug: Cyclophosphamide · Drug: Fludarabine

  • Experimental
    Phase 1b Dose Expansion

    * Dose Confirmation of AB-201 in advanced metastatic breast cancer, gastric or gastroesophageal junction adenocarcinoma with HER2 overexpression * Interventions: * Drug: AB-201 * Drug: Cyclophosphamide * Drug: Fludarabine

    Drug: AB-201 · Drug: Cyclophosphamide · Drug: Fludarabine

Interventions

06

What researchers measure

Primary outcomes

  1. Incidence, severity, seriousness, and dose relationship of Adverse Events [Safety & Tolerability]

    Adverse events and laboratory abnormalities will be graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) version 5.0.

    Time frame: up to 18 months per patient

  2. Determination of Recommended Phase 2 Dose (RP2D)

    Assessment of Dose-Limiting Toxicities(DLTs), pharmacokinetics (PK), safety, and objective response rate (ORR) per the Response Evaluation Criteria for Solid Tumors (RECIST) v1.1 in subjects with HER2+ breast cancer and gastric/GEJ cancer. PK: Monitor persistence of AB-201 in subjects samples collected prior to and following AB-201 administration.

    Time frame: up to 18 months per patient

Secondary outcomes

  1. To determine the preliminary efficacy, by the objective response rate (ORR) per the Response Evaluation Criteria for Solid Tumors (RECIST) v1.1, of AB-201 in subjects with advanced HER2+ solid tumors

    The proportion of subjects who experienced an PR or CR, as assessed by investigators per RECIST v1.1.

    Time frame: up to 18 months per patient

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Oct 2024; primary completion for Apr 2027, 30 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 14, 2024
First posted
Apr 2, 2024
StartEst.
Oct 31, 2024
Primary completionEst.
Apr 2027
CompletionEst.
Feb 2029
Last update
Jan 24, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 24, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06341647
Lead sponsor
GC Cell Corporation
Responsible party
Sponsor
First posted
Apr 2, 2024
Start date
Oct 31, 2024 (estimated)
Primary completion
Apr 2027 (estimated)
Completion
Feb 2029 (estimated)
Last update
Jan 24, 2025

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is withdrawn, as verified in Jan 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Anpocogin

Start the discussion